Please login to the form below

Fishawack Health adds market access and commercial strategy consultancy Skysis as part of its bold growth plans

Fishawack Health, the global healthcare communications agency, announces the acquisition of Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.

We’re delighted to announce the addition of Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US, to the Fishawack Health group. Fishawack Health is the parent company of Blue Latitude Health, we unite with the capabilities across the group to best serve our clients' needs.

Skysis brings with it the ability to connect interdependencies across healthcare profession, payer, channel, and patient stakeholders. It is the first acquisition with Fishawack Health’s new investor Bridgepoint. The acquisition bolsters our strong consulting capabilities and furthers our skills in market access.

Clients can benefit from these services across our three capabilities – marketing and commercial consulting, medical communications, and commercial and creative execution. Each of these services is underpinned shared world-class resources, including digital expertise, insight, data analytics and visualisation, and media and production. These capabilities work independently or combine seamlessly as one unit, complete with teams tailored to the client’s individual needs and challenges. As a result, our clients can utilise Skysis’ skills in combination with a wide range of services.

Oliver Dennis, Fishawack Health co-founder and CEO, said: “In partnering with Bridgepoint, we have made a step-change in our ambition. We’re delighted today to add Skysis to the group. They bring strategy and market access across the entire commercial life cycle, making them an important addition to our strategic consulting capabilities.”

Fred Bassett, Head of Consulting for Fishawack Health, added: “Skysis provides strategy and execution across every stage of the commercial life cycle. The company’s expertise bolsters Fishawack Health’s strong strategic consulting team, which includes analysts, researchers, commercial consultants, market access and customer experience specialists, and boasts a network of Physician Expert Partnerships.”

Providing further detail, Dan Twibell Managing Director of Skysis, explained: “We wanted to partner with a group that could help us scale our business, offer more solutions to our clients and that our team would be excited to join.”

Dawn Rich, Managing Director of Skysis, said: “Our team is thrilled to be joining Fishawack Health. Our core capabilities match perfectly with the key services of the wider consulting capability.”

Our strategic and scientific focus as a united group makes us ideally placed to solve complex brand, portfolio and enterprise-level challenges for its clients. With experience across every major therapeutic category, we understand what it takes to improve patient outcomes and drive business success. Fishawack Health will continue to add new capabilities designed to solve our client’s critical medical and commercial challenges in an integrated and seamless way.

Contact hello@bluelatitude.com to find out how we can help you solve your healthcare challenges.

20th April 2020

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Three strategies for managing loss of exclusivity successfully
Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health